Results 61 to 70 of about 16,479 (221)

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity ...
Lucy Galloway, Cinzia Dello Russo, Nicholas Bass, Elvira Bramon, Helen Cross, Natalie Curley, Sarah Curran, Helen Davies, Jana De Villiers, William Evans, Bernhard Frank, Alice Groves, Judith Hayward, Jon Higham, Dyfrig A. Hughes, Shwe Sin Kyaw, Anthony G. Marson, Ailsa McLellan, Seth Mensah, Francis O'Neill, Jane Sargison, Sanjay M. Sisodiya, Jill Swan, Joanna M. Zakrewska, Munir Pirmohamed   +24 more
wiley   +1 more source

Oxcarbazepine-induced Reversible Pancytopenia and Severe Hyponatremia in a Patient with Bipolar Affective Disorder: Two Case Reports

Journal of Clinical and Diagnostic Research
Oxcarbazepine is a widely used mood stabiliser in Bipolar Affective Disorder (BPAD) due to its favourable tolerability compared with carbamazepine. However, it is associated with serious adverse effects, including hyponatraemia and pancytopenia, which ...
Sowmya Peyouse, S Gopinath, Priya Shivashankar   +2 more
doaj   +1 more source

Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis [PDF]

, 2013
The authors would like to thank the support of the National Multiple Sclerosis Society (USA) and the Multiple Sclerosis Society of Great Britain and Northern ...
Al-Izki, S, Amor, S, Baker, D, Browne, L, Chan, AWE, Clutterbuck, L, Garthwaite, J, Gerritsen, WH, Giovannoni, G, Hankey, DJR, Joel, SP, Lidster, K, Montoya, A, Peferoen-Baert, R, Perkins, V, Posada, C, Pryce, G, Selwood, DL, Ummenthum, K, van der Valk, P, von Kutzleben, SM   +20 more
core   +2 more sources

Drug Critical Limits for Urgent Physician Notification

Clinical Pharmacology &Therapeutics, EarlyView.
Critical limits represent quantitative decision thresholds for drugs that require immediate clinician notification and potential life‐saving intervention. United States hospitals lack a national standard for drug critical limits. We collected critical limits from 417 US hospitals across all 50 states and Washington, D.C.; of these, 411 maintained drug ...
Elina Kuang, Yasmeen Ibrahim, Kyle Cheng, Gerald J. Kost   +3 more
wiley   +1 more source

Epilepsy characteristics in patients with muscle‐eye‐brain disease: A systematic review of electroclinical features

Epileptic Disorders, EarlyView.
Abstract Background and Objectives Muscle‐Eye‐Brain disease (MEB) is a dystroglycanopathy that belongs to the congenital muscular dystrophies. Central nervous system manifestations include congenital brain abnormalities, neurodevelopmental delay, and epilepsy, making it a rare but important cause of developmental and epileptic encephalopathy.
Stefania Kalampokini, Evripidis Pityrigkas, Eleni Liouta, Georgia Pepe, Vasiliki Poulidou, Martha Spilioti, Vasilios K. Kimiskidis   +6 more
wiley   +1 more source

Vitamin D status among children and adolescents on anticonvulsant drugs in Southern Switzerland

Swiss Medical Weekly, 2014
INTRODUCTION: It is recognised that vitamin D status is often inadequate (
Vera Ramelli, Gian Paolo Ramelli, Sebastiano A. G. Lava, Giordano M. Siegenthaler, Marco Cantù, Mario G. Bianchetti, Alessandro Ceschi   +6 more
doaj   +1 more source

Antiepileptic drugs in pregnancy and lactation [PDF]

, 2008
No antiepileptic drug is completely safe to use in pregnancy as the risk of fetal abnormality is increased. Valproate should be avoided if possible because of the risk of major malformations.
Lander, Cecile M.
core   +1 more source

Effectiveness and safety of cenobamate after conversion to monotherapy or dual therapy in real‐world clinical practice

Epileptic Disorders, EarlyView.
Abstract Objective Patients with drug‐resistant epilepsy (DRE) typically take multiple anti‐seizure medications (ASMs) and are at risk of treatment‐related adverse events (AEs). This study assessed the impact of cenobamate monotherapy or dual therapy in patients with drug‐resistant epilepsy.
Álvaro Sánchez‐Guijo Benavente, Guillermina García Martín, Estuardo Daniel Castro Ruiz, Pablo Cabezudo García, Yolanda López Moreno, José Carlos Estévez María, Irene Lorite Fuentes, Sergio Navarro Conti, Raquel Calle Calle, Alejandro Fernández Cabrera, Isabel Ros González, Dulce Campos Blanco, María Isabel Chamorro Muñoz, Pedro Jesús Serrano Castro   +13 more
wiley   +1 more source

Risk-Benefits of Oxcarbazepine vs Carbamazepine

Pediatric Neurology Briefs, 2004
The clinical differences between oxcarbazepine (OXC) and carbamazepine (CBZ) are reviewed in terms of efficacy, tolerability, and interaction with other drugs in a study at Universitat Bonn, Berlin, Germany.
J Gordon Millichap
doaj   +1 more source

Induction of cytochrome P450 2C9 and P‐glycoprotein activity by antiseizure medications: A systematic review and network meta‐analysis

Epileptic Disorders, EarlyView.
Abstract Objectives Antiseizure medications (ASMs) can induce the activity of drug‐metabolizing enzymes and drug transporters, including cytochrome P450 (CYP)2C9 and P‐glycoprotein (P‐gp). Our objective was to comparatively assess the effects of ASMs on exposure to clinical CYP2C9 and P‐gp substrates.
Hagar Cohen, Nahawand Bahash, Tomer Ben‐Shushan, Ilan Matok, Sara Eyal   +4 more
wiley   +1 more source